Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CEP-28122 mesylate salt, a diaminopyrimidine derivative, serves as a potent, selective, and orally bioavailable ALK (anaplastic lymphoma kinase) inhibitor, exhibiting an IC 50 value of 1.9 nM against recombinant ALK kinase activity. It demonstrates antitumor efficacy in ALK-positive human cancer experimental models and possesses favorable pharmacodynamic and pharmacokinetic profiles.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 98.00 |
Description | CEP-28122 mesylate salt, a diaminopyrimidine derivative, serves as a potent, selective, and orally bioavailable ALK (anaplastic lymphoma kinase) inhibitor, exhibiting an IC 50 value of 1.9 nM against recombinant ALK kinase activity. It demonstrates antitumor efficacy in ALK-positive human cancer experimental models and possesses favorable pharmacodynamic and pharmacokinetic profiles. |
Molecular Weight | 635.17 |
Formula | C29H39ClN6O6S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CEP-28122 mesylate salt inhibitor inhibit